Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group.
Berkowitz SD, Sane DC, Sigmon KN, Shavender JH, Harrington RA, Tcheng JE, Topol EJ, Califf RM. Berkowitz SD, et al. Among authors: sigmon kn. J Am Coll Cardiol. 1998 Aug;32(2):311-9. doi: 10.1016/s0735-1097(98)00252-6. J Am Coll Cardiol. 1998. PMID: 9708455 Free article. Clinical Trial.
Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial.
Moliterno DJ, Califf RM, Aguirre FV, Anderson K, Sigmon KN, Weisman HF, Topol EJ. Moliterno DJ, et al. Among authors: sigmon kn. Am J Cardiol. 1995 Mar 15;75(8):559-62. doi: 10.1016/s0002-9149(99)80616-x. Am J Cardiol. 1995. PMID: 7887377 Clinical Trial.
Clinical importance of thrombocytopenia occurring in the hospital phase after administration of thrombolytic therapy for acute myocardial infarction. The Thrombolysis and Angioplasty in Myocardial Infarction Study Group.
Harrington RA, Sane DC, Califf RM, Sigmon KN, Abbottsmith CW, Candela RJ, Lee KL, Topol EJ. Harrington RA, et al. Among authors: sigmon kn. J Am Coll Cardiol. 1994 Mar 15;23(4):891-8. doi: 10.1016/0735-1097(94)90634-3. J Am Coll Cardiol. 1994. PMID: 8106694 Free article. Clinical Trial.
Modifiable risk factors for vascular access site complications in the IMPACT II Trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis.
Mandak JS, Blankenship JC, Gardner LH, Berkowitz SD, Aguirre FV, Sigmon KN, Timmis GC, Gilchrist IC, McIvor M, Resar J, Weiner BH, George BS, Talley JD, Lincoff AM, Tcheng JE, Califf RM, Topol EJ. Mandak JS, et al. Among authors: sigmon kn. J Am Coll Cardiol. 1998 Jun;31(7):1518-24. doi: 10.1016/s0735-1097(98)00130-2. J Am Coll Cardiol. 1998. PMID: 9626829 Free article. Clinical Trial.
Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II.
Tardiff BE, Califf RM, Tcheng JE, Lincoff AM, Sigmon KN, Harrington RA, Mahaffey KW, Ohman EM, Teirstein PS, Blankenship JC, Kitt MM, Topol EJ. Tardiff BE, et al. Among authors: sigmon kn. J Am Coll Cardiol. 1999 Jan;33(1):88-96. doi: 10.1016/s0735-1097(98)00551-8. J Am Coll Cardiol. 1999. PMID: 9935014 Free article. Clinical Trial.
Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT-II). Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis.
Thel MC, Califf RM, Tardiff BE, Gardner LH, Sigmon KN, Lincoff AM, Topol EJ, Kitt MM, Blankenship JC, Tcheng JE. Thel MC, et al. Among authors: sigmon kn. Am J Cardiol. 2000 Feb 15;85(4):427-34. doi: 10.1016/s0002-9149(99)00767-5. Am J Cardiol. 2000. PMID: 10728945 Clinical Trial.
45 results